Icu Medical Inc/de 10-Q quarterly reports

ICU Medical Inc. announced its second-quarter results, showcasing significant revenue increases in Infusion Systems and Consumables, alongside a notable improvement in gross margins driven by tariff refunds and strategic divestitures.

ICU Medical reports improved profitability and significant debt reduction in Q3 2025, despite a revenue decline and ongoing regulatory and tariff pressures.

ICU Medical reports a return to net income and improved gross margins in Q2 2025, driven by the strategic divestiture of its IV Solutions business and significant debt reduction, despite an overall revenue decline and new FDA regulatory challenges.

ICU Medical's Q1 2025 shows revenue growth driven by consumables and infusion systems, but the company still reports a net loss due to restructuring and integration expenses.

ICU Medical saw a revenue increase in Q3 2024, but experienced a net loss, influenced by restructuring and integration expenses, and a valuation allowance against deferred tax assets.

ICU Medical's second quarter results show a net loss despite revenue growth, influenced by restructuring, integration costs, and foreign exchange impacts.

ICU Medical's first quarter of 2024 saw a net loss of $39.5 million, impacted by currency fluctuations and lower production volumes, despite a slight revenue decrease.